secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001437749-24-030764
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar initiates Phase 1a trial of MNPR-101-Lu radiopharmaceutical therapy in advanced cancers
--------------------------------------------------------------------------------

- Phase 1a open-label dose-escalation study of MNPR-101-Lu in solid tumors now recruiting.
- First site activated: Melbourne Theranostic Innovation Centre in Australia.
- Trial open only to patients in ongoing MNPR-101-Zr Phase 1 imaging/dosimetry trial.
- MNPR-101 targets uPAR, expressed in pancreatic, breast, colorectal, ovarian, and bladder cancers.
- CEO says trial launched months ahead of original schedule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924030764/0001437749-24-030764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924030764/mnpr20241004_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer